ClinicalTrials.gg
RecruitingNCT06747429HF4HFUpdated May 26, 2026

High Fat Diet for Cardiac Metabolic Reprogramming

An interventional study of High fat diet and Standard diet in Non-ischemic Dilated Cardiomyopathy and Heart Failure With Reduced Ejection Fraction, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Heart Failure with a site in Spain — 76 open to participants now, 99 under way, 21 of them phase 3. Heart Failure · Spain.

Planned enrollment
209th of 263
80 · median 294
Started
2026
with 21 others
No phase
119 of 342
34 open now
Primary completion
2026-06
later than 22 of 98 live
Registered
293rd of 342
by date

Among the 342 studies in Heart Failure with a site in Spain, this one is the 209th largest by planned enrollment of the 263 interventional ones that give a count, is one of 22 that started in 2026, is one of 119 with no phase, reaches primary completion later than 22 of the 98 other live ones, and was the 293rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

76 of the 342 studies in Heart Failure with a site in Spain are open now. Recruiting first, the newest first:

70 more — sign in →

All 76 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Heart Failure with a site in Spain, or all of them as a file.
02

Study summary

Heart failure (HF) continues to be a leading cause of morbidity and mortality worldwide, despite advances in treatment. HF is often characterized by an altered metabolism in the heart, where glucose is favored over fatty acids as the primary energy substrate. This metabolic shift has been hypothesized to contribute to disease progression. Previous studies using animal models have demonstrated that restoring fatty acid metabolism through dietary intervention can reverse the adverse metabolic effects and improve heart function. A transgenic murine model with mitochondrial defects, for instance, exhibited improved cardiac function after an HFD intervention. These findings were reinforced by a translational pig model of non-ischemic DCM, where a high-fat diet significantly improved LVEF compared to a standard diet.

Building upon these promising preclinical results, a small-scale human study showed that lipid infusion, rather than glucose, improved cardiac function in HF patients. However, the long-term benefits of a HFD in heart failure patients have yet to be thoroughly explored. The HF4HF trial aims to fill this gap by evaluating the effects of an HFD over a two-month period in patients with non-ischemic DCM and reduced LVEF.

The "High Fat Diet for Heart Failure" (HF4HF) study is a proof-of-concept randomized controlled trial designed to investigate the efficacy of a high-fat diet (HFD) as a therapeutic intervention in patients with non-ischemic dilated cardiomyopathy (DCM) and reduced left ventricular ejection fraction (LVEF). The study hypothesizes that cardiac metabolic reprogramming, achieved through a controlled nutritional intervention involving an HFD, can enhance systolic function, myocardial energetics, and overall heart function in heart failure (HF) patients. Cofunded by the European Commission and national entities, the trial is spearheaded by a consortium of cardiovascular research centers across four countries: Spain, Italy, France, and Romania.

Read the detailed description

Despite the notable therapeutic advancements, heart failure (HF) remains a significant cause of morbi-mortality worldwide, that justifies the need of identifying novel treatment strategies targeting non-redundant disease pathways.The heart, being the organ with the highest energy demands, produces over 5 kg of adenosine triphosphate (ATP) per day under normal conditions to support its functions. To meet this substantial energy requirement, the myocardium utilizes various substrates, being the oxidation of fatty acids the primary source, due to their efficiency in ATP production compared to carbohydrates and amino acids.However, HF, regardless of its etiology and across the entire spectrum of left ventricular ejection fraction (LVEF), often involves an altered cardiac metabolism characterized by a preference for glucose over fatty acids as an energy source.While previously considered a protective mechanism, recent findings challenge this notion.

Preclinical investigations using a transgenic murine model with mitochondrial alterations in cardiomyocytes revealed a shift in energy substrate utilization from fatty acids to glucose, resulting in progressive dilated cardiomyopathy (DCM) with reduced ejection fraction. Administering a high-fat diet (HFD) to these mice restored normal myocardial metabolism, leading to disease regression.Building upon these findings, a subsequent study was conducted by members of HF4HF Consortium, in a translational pig model of non-ischemic DCM and LVEF \<50%, through the generation of hibernated myocardium. These pigs were randomly assigned to either a standard diet (regular chow) or a HFD (80% regular chow plus 20% lard, rich in palmitic, oleic, stearic and linoleic acids). Following a two-month intervention, pigs receiving the HFD showed a significant increase in LVEF from 41% to 56%, compared to controls whose LVEF only slightly changed from 40% to 38% (p 0.012).

At the end of the protocol, the cardiomyocytes from pigs who were on regular diet displayed fragmented mitochondria and presence of abundant lipid droplets, suggestive of poor lipid trafficking and storage. At a molecular level, hibernated myocardium with HF was associated with a significant downregulation of proteins involved in lipid import from cytosol to mitochondria (CRAT and ACOX1), along with a compensatory upregulation of glucose transport proteins (GLUT1), something that was completely restored after 2 months of HFD. Altogether, these data show that HF is associated with an impaired intracellular fatty acid traffic responsible for the metabolic switch. HFD was able to revert the altered lipid handling, allowing a metabolic reprograming having mitochondria use again fatty acids. The metabolic reprograming was further reinforced by the in vivo 18F-FDG PET studies, which showed a significant modification in the glucose uptake in HFD versus control diet pigs. All these outstanding results underscored the potential of high-fat dietary intervention in ameliorating systolic function in non-ischemic DCM.

Finally, a recent human study involving 20 patients with non-ischemic HF and reduced LVEF examined the effects of intravenous glucose plus insulin infusion versus lipid infusion of long-chain fatty acids, in terms of cardiac function and energetics, assessed by cardiovascular magnetic resonance (CMR) and MR spectroscopy 1 hour after the infusion. The lipid infusion notably enhanced cardiac function, increasing LVEF from 35% to 40%, whereas glucose plus insulin infusion showed no impact on disease parameters. Moreover, significant improvements in diastolic function, and myocardial energetics, assessed by 13P and the phosphocreatine/ATP ratio, were reported after intralipid infusion; findings that support the hypothesis of remaining metabolic substrate flexibility of the failing heart. However, this study only assessed the acute effects of lipid exposure on cardiac function and energetics, lacking long-term evidence regarding the efficacy of employing a high-fat dietary pattern in HF management. Nonetheless, this novel approach holds promise in the medical-nutritional management of this prevalent disease.

03

Conditions studied

  • Non-ischemic Dilated Cardiomyopathy
  • Heart Failure With Reduced Ejection Fraction

Browse trials for

Keywords

  • heart failure
  • high-fat diet
  • clinical trial
  • non-ischemic DCM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes and ≥18 years old
  • Patients diagnosed with HF secondary to non-ischemic DCM, according to ESC guidelines definition,1 with or without a known genetic basis.
  • ≤49% according to the baseline CMR.
  • Optimized HF guideline-directed medical therapy for at least 3 months prior to inclusion.
  • Patients who have provided .

Exclusion criteria

Exclusion Criteria:

  • Prior diagnosis of ischemic DCM.
  • Prior diagnosis of established atherosclerotic cardiovascular disease (angina/myocardial infarction, /stroke, lower limb ischemia or at any other peripheral level).
  • Changes in HF therapies within the last 3 months.
  • HF decompensation within the previous 3 months, including HF hospitalization or the need of ambulatory intravenous diuretic or inotropic treatment such as levosimendan.
  • Uncontrolled dyslipidemia, defined as LDL-cholesterol >160 mg/dL and/or triglycerides >200 mg/dL, despite treatment.
  • Any for CMR:

Severe claustrophobia. Any device which is known to threaten or pose hazard in all MR environments. //www.mrisafety.com/ Patients with implanted biomedical devices (cardiac artefacts): pacemakers, cardiac defibrillators or cardiac resynchronization therapy.

  • Liver and biliary diseases, including prior diagnosis of non-alcoholic fatty liver disease and unoperated cholelithiasis.
  • Prior episodes of acute pancreatitis or chronic pancreatitis.
  • Prior fish or nut allergy.
  • less than 12 months.
  • Pregnancy or planned pregnancy for the next 4 months.
  • Current lactation.
  • Patients participating in other randomized clinical trial.
  • Impossibility to consent or undergo study follow-up
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    High fat diet

    Patients receiving a high-fat diet

    Other: High fat diet

  • Active comparator
    Control

    Patients receiving a standard diet

    Other: Standard diet

Interventions

  • OtherHigh fat diet

    Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 70% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and the remaining calories from carbohydrates (10-20%).

  • OtherStandard diet

    Weekly isocaloric dietary profile, with total daily energy intake distributed as follows: 30% from fats, primarily sourced from nuts, extra virgin olive oil, avocados, and animal fats from fish and cheese; protein intake of 0.8-1.2 g per kg body weight (10-20%); and 50-60% from carbohydrates.

06

What researchers measure

Primary outcomes

  1. Changes in left ventricular ejection fraction (LVEF)

    Changes in LVEF assessed using cardiac magnetic resonance imaging (CMR)

    Time frame: At baseline, month 2 and month 4

Secondary outcomes

  1. Left ventricular strain

    Changes in left ventricular strain assessed using cardiac magnetic resonance imaging (CMR)

    Time frame: At baseline, month 2 and month 4

  2. Diastolic function

    Changes in diastolic function assessed using cardiac magnetic resonance imaging (CMR)

    Time frame: At baseline, month 2 and month 4

  3. White blood cells

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  4. Red blood cells

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  5. Hemoglobin

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  6. Platelets

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  7. Glucose

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  8. HDL-cholesterol

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  9. LDL-cholesterol

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  10. Triglycerides

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  11. Electrolytes (sodium, potassium, calcium, magnesium)

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  12. Kidney function (creatinine, urea)

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  13. Vitamins (vitamin B12, 25-OH Vitamin D, folate)

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  14. Albumin

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  15. Iron metabolism (iron, ferritin)

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  16. Liver function (AST, ALT, γGT)

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

  17. C-reactive protein

    Quantification with standard laboratory procedures

    Time frame: At baseline, month 2 and month 4

07

Study locations

3 of 5 sites recruiting
  • Hôpital Européen Georges Pompidou, INSERM
    Paris, France
    Not yet recruiting
  • University of Florence, Clinical and Experimental Medicine, Unit of Clinical Nutrition,
    Florence, Italy
    Not yet recruiting
  • University of Medicine and Pharmacy "Carol Davila", Bucharest,
    Bucharest, Romania
    Recruiting
  • Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro (IIS),
    Madrid, Spain
    Recruiting
    • Pablo García Pavía, MD PhD · Contact
    • Pablo García Pavía, MD PhD · Principal investigator
  • Hospital Universitario Fundación Jiménez Díaz,
    Madrid, Spain
    Recruiting
08

References and documents

Publications

  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021 Dec 21;42(48):4901. doi: 10.1093/eurheartj/ehab670. No abstract available. PubMed 34649282 ↗
  • Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013 Aug 30;113(6):709-24. doi: 10.1161/CIRCRESAHA.113.300376. PubMed 23989714 ↗
  • Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, Des Rosiers C, Gerszten R, Glatz JF, Griffin JL, Gropler RJ, Holzhuetter HG, Kizer JR, Lewandowski ED, Malloy CR, Neubauer S, Peterson LR, Portman MA, Recchia FA, Van Eyk JE, Wang TJ; American Heart Association Council on Basic Cardiovascular Sciences. Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association. Circ Res. 2016 May 13;118(10):1659-701. doi: 10.1161/RES.0000000000000097. Epub 2016 Mar 24. PubMed 27012580 ↗
  • Wai T, Garcia-Prieto J, Baker MJ, Merkwirth C, Benit P, Rustin P, Ruperez FJ, Barbas C, Ibanez B, Langer T. Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice. Science. 2015 Dec 4;350(6265):aad0116. doi: 10.1126/science.aad0116. PubMed 26785494 ↗
  • Martinez-Milla J, Galan-Arriola C, Carnero M, Cobiella J, Perez-Camargo D, Bautista-Hernandez V, Rigol M, Solanes N, Villena-Gutierrez R, Lobo M, Mateo J, Vilchez-Tschischke JP, Salinas B, Cusso L, Lopez GJ, Fuster V, Desco M, Sanchez-Gonzalez J, Ibanez B. Translational large animal model of hibernating myocardium: characterization by serial multimodal imaging. Basic Res Cardiol. 2020 Apr 14;115(3):33. doi: 10.1007/s00395-020-0788-0. PubMed 32291522 ↗
  • Watson WD, Green PG, Lewis AJM, Arvidsson P, De Maria GL, Arheden H, Heiberg E, Clarke WT, Rodgers CT, Valkovic L, Neubauer S, Herring N, Rider OJ. Retained Metabolic Flexibility of the Failing Human Heart. Circulation. 2023 Jul 11;148(2):109-123. doi: 10.1161/CIRCULATIONAHA.122.062166. Epub 2023 May 18. PubMed 37199155 ↗
  • Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, Bucciarelli-Ducci C, Croisille P, Dall'Armellina E, Dharmakumar R, Eitel I, Fernandez-Jimenez R, Friedrich MG, Garcia-Dorado D, Hausenloy DJ, Kim RJ, Kozerke S, Kramer CM, Salerno M, Sanchez-Gonzalez J, Sanz J, Fuster V. Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019 Jul 16;74(2):238-256. doi: 10.1016/j.jacc.2019.05.024. PubMed 31296297 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared to protect participants' privacy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 5 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartActual
Jan 15, 2026
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747429
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Collaborators
Puerta de Hierro University Hospital, European Georges Pompidou Hospital, Carol Davila University of Medicine and Pharmacy, University of Florence, Hospital Universitario Fundación Jiménez Díaz
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jan 15, 2026
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 26, 2026

Study contacts

Carlos Nicolás Pérez-García, MD PhD.
Contact
carlosnicolas.perez@cnic.es
(+34) 914531200 ext. 5400
Claudia Artiaga, MSc
Contact
cartiaga@cnic.es
(+34) 914531200 ext. 5400
Francesco Sofi, MD PhD
principal investigator · University of Florence, Clinical and Experimental Medicine, Unit of Clinical Nutrition, Florence,
Pablo García Pavía,, MD PhD
principal investigator · Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro (IIS), Hospital Universitario Puerta de Hierro Majadahonda
Ruxandra Jurcut, MD PhD
principal investigator · University of Medicine and Pharmacy "Carol Davila", Bucharest,
Jean-Sébastian Hulot, MD PhD
principal investigator · Hôpital Européen Georges Pompidou, INSERM, Paris,
Mikel Taibo Urquía, MD
principal investigator · Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Borja Ibánez,, MD PhD
study chair · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion